Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Qingjian Wang.
Fibrogenesis & Tissue Repair | 2011
Qingjian Wang; William R. Usinger; Blake Nichols; Julia Gray; Leon Xu; Todd W Seeley; Mitch Brenner; Guangjie Guo; Weihua Zhang; Noelynn A. Oliver; Al Lin; David A. Yeowell
BackgroundConnective tissue growth factor (CTGF) is widely thought to promote the development of fibrosis in collaboration with transforming growth factor (TGF)-β; however, most of the evidence for its involvement comes from correlative and culture-based studies. In this study, the importance of CTGF in tissue fibrosis was directly examined in three murine models of fibrotic disease: a novel model of multiorgan fibrosis induced by repeated intraperitoneal injections of CTGF and TGF-β2; the unilateral ureteral obstruction (UUO) renal fibrosis model; and an intratracheal bleomycin instillation model of pulmonary fibrosis.ResultsIntraperitoneal coadministration of CTGF and TGF-β2 elicited a profound fibrotic response that was inhibited by the human anti-CTGF antibody FG-3019, as indicated by the ability of FG-3019 to ameliorate the histologic signs of fibrosis and reduce the otherwise increased hydroxyproline:proline (Hyp:Pro) ratios by 25% in kidney (P < 0.05), 30% in liver (P < 0.01) and 63% in lung (P < 0.05). Moreover, administration of either cytokine alone failed to elicit a fibrotic response, thus demonstrating that CTGF is both necessary and sufficient to initiate fibrosis in the presence of TGF-β and vice versa. In keeping with this requirement for CTGF function in fibrosis, FG-3019 also reduced the renal Hyp:Pro response up to 20% after UUO (P < 0.05). In bleomycin-injured animals, a similar trend towards a FG-3019 treatment effect was observed (38% reduction in total lung Hyp, P = 0.056). Thus, FG-3019 antibody treatment consistently reduced excessive collagen deposition and the pathologic severity of fibrosis in all models.ConclusionCooperative interactions between CTGF and TGF-β signaling are required to elicit overt tissue fibrosis. This interdependence and the observed anti-fibrotic effects of FG-3019 indicate that anti-CTGF therapy may provide therapeutic benefit in different forms of fibroproliferative disease.
Archive | 2002
Stephen J. Klaus; Al Y. Lin; Thomas B. Neff; Qingjian Wang; Volkmar Guenzler-Pukall; Michael P. Arend; Lee A. Flippin
Archive | 2002
Volkmar Guenzler-Pukall; Thomas B. Neff; Qingjian Wang; Michael P. Arend; Lee A. Flippin; Alex Melekhov
Archive | 2004
Al Y. Lin; Thomas B. Neff; Noelynn A. Oliver; William R. Usinger; Qingjian Wang; David A. Yeowell
Archive | 2008
Al Y. Lin; Thomas B. Neff; Noelynn A. Oliver; William R. Usinger; Qingjian Wang; David A. Yeowell
Archive | 2006
Stephen J. Klaus; Qingjian Wang; Thomas B. Neff
Archive | 2005
Allan Flyvbjerg; Guangjie Guo; David Y. Liu; Thomas B. Neff; Noelynn A. Oliver; William R. Usinger; Qingjian Wang
Archive | 2010
Allan Flyvbjerg; Guangjie Guo; David Y. Liu; Thomas B. Neff; Noelynn A. Oliver; William R. Usinger; Qingjian Wang
Archive | 2011
Stephen J. Klaus; Al Y. Lin; Thoams B. Neff; Qingjian Wang; Volkmar Guenzler-Pukall; Michael P. Arend; Lee A. Flippin; Alex Melekhov
Archive | 2002
Volkmar Guenzler-Pukall; Thomas B. Neff; Qingjian Wang; Michael P. Arend; Lee A. Flippin